Durgical
EN
Open the app

Osilodrostat

  • Adrenal steroid synthesis inhibitorsAdrenal steroid synthesis inhibitors

An oral blocker of the last enzyme in cortisol synthesis. It lowers cortisol in Cushing's syndrome when surgery is not possible or has failed.

Updated

Quick facts

Group
Adrenal steroid synthesis inhibitors
Target
11-beta-hydroxylase (CYP11B1), and aldosterone synthase (CYP11B2)
Used for
Endogenous Cushing's syndrome
Key effects
Nausea · Headache and tiredness · Swelling of the legs
Monitor
Cortisol levels · ECG before and during treatment
ATC
H02CA02

No doses: the clinician sets them by the current guideline.

Mechanism of action

The figure shows osilodrostat bound to the heme of human aldosterone synthase (CYP11B2), a very similar enzyme that osilodrostat also inhibits; CYP11B1, its main target for cortisol, has the same kind of site.

Target in 3D: 11-beta-hydroxylase (CYP11B1), and aldosterone synthase (CYP11B2). PDB structure 7M8V (RCSB PDB, public domain). View the structure at RCSB PDB

Osilodrostat is a non-steroidal inhibitor of 11-beta-hydroxylase (CYP11B1), which converts 11-deoxycortisol to cortisol, and of aldosterone synthase (CYP11B2). Cortisol falls. Precursors before the block accumulate: 11-deoxycortisol and deoxycorticosterone (mineralocorticoid effects: low potassium, oedema, high blood pressure) and adrenal androgens (hirsutism, acne). Too much effect causes adrenal insufficiency.

  1. Osilodrostat binds the heme of CYP11B1 (and CYP11B2)
  2. 11-deoxycortisol is not converted to cortisol
  3. Cortisol falls; precursors and androgens accumulate
  4. Doses are titrated to avoid adrenal insufficiency

Indications

  • Endogenous Cushing's syndrome (including Cushing's disease) when pituitary surgery is not possible or has not cured it Cushing syndrome →

Adverse effects

Common

  • Nausea, vomiting, diarrhoea, abdominal pain and reduced appetite
  • Headache and tiredness
  • Swelling of the legs (oedema)
  • Excess hair growth and acne in women
  • Dizziness on standing

Contraindications

  • Hypersensitivity to osilodrostat
  • Caution: long QT, other heart disease, uncorrected low potassium or magnesium

Key interactions

Other drugs that prolong the QT interval
Additive QT prolongation; ECG monitoring
Other medicines in general
Doses may need adjusting or closer monitoring; a full medication list is reviewed

What is monitored

  • Cortisol levels (urine or serum) during dose titration
  • ECG before and during treatment
  • Potassium and magnesium
  • Blood pressure and signs of adrenal insufficiency

Administration and safety

  • Oral tablets on a regular schedule; started low and adjusted gradually
  • Low potassium and magnesium are corrected before starting
  • Not stopped without the prescriber, who may lower or interrupt it if cortisol falls too far

Pregnancy and breastfeeding

Data in pregnancy are limited; the prescriber is told about pregnancy plans. Breastfeeding is avoided during treatment and for a week after the last dose.

Nursing care

  • Teach the signs of low cortisol: nausea, vomiting, tiredness, abdominal pain, loss of appetite, dizziness
  • Check ECG and electrolyte results
  • Advise rising slowly from lying or sitting
  • Laboratory staff are told the person takes osilodrostat

Pharmacokinetics

Absorption
Taken by mouth, with or without food

Test yourself

Think of the answer, then tap the question to see it.

Which enzyme does osilodrostat mainly inhibit to lower cortisol?

11-beta-hydroxylase (CYP11B1), the final step from 11-deoxycortisol to cortisol; it also inhibits aldosterone synthase.

Why can osilodrostat cause hypokalaemia and oedema?

Precursors before the block, such as deoxycorticosterone, accumulate and have mineralocorticoid activity.

Which cardiac test is done before and during osilodrostat?

An ECG, because the drug can prolong the QT interval.

Add to my cards (3)

More Pharmacology questions →

Connections

← Back to the class: Adrenal steroid synthesis inhibitors

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: Osilodrostat: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.